{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:27:59Z","timestamp":1793816879468,"version":"4.6.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Quanzhou High-level Talents Innovation and Entrepreneurship Project","award":["2024QZC005YR"],"award-info":[{"award-number":["2024QZC005YR"]}]},{"DOI":"10.13039\/100016808","name":"Natural Science Foundation of Xiamen Municipality","doi-asserted-by":"publisher","award":["3502Z202573050"],"award-info":[{"award-number":["3502Z202573050"]}],"id":[{"id":"10.13039\/100016808","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2025J01169"],"award-info":[{"award-number":["2025J01169"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"DOI":"10.1007\/s11030-026-11628-w","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:40:11Z","timestamp":1782859211000},"page":"9791-9812","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Design, synthesis and biological evaluations of novel VEGFR-2 inhibitors based on Fruquintinib and Cabozantinib"],"prefix":"10.1007","volume":"30","author":[{"given":"Xueyan","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heliang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengling","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aike","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfa","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaosheng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5844-9984","authenticated-orcid":false,"given":"Junjie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"issue":"1","key":"11628_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A (2025) Cancer statistics. CA Cancer J Clin 75(1):10\u201345","journal-title":"CA Cancer J Clin"},{"issue":"13","key":"11628_CR2","doi-asserted-by":"publisher","first-page":"6370","DOI":"10.7150\/thno.57828","volume":"11","author":"GQ Wei","year":"2021","unstructured":"Wei GQ, Wang Y, Yang G, Wang Y, Ju R (2021) Recent progress in nanomedicine for enhanced cancer chemotherapy. Theranostics 11(13):6370\u20136392","journal-title":"Theranostics"},{"key":"11628_CR3","doi-asserted-by":"publisher","first-page":"195","DOI":"10.20517\/evcna.2022.20","volume":"3","author":"RH Eibl","year":"2022","unstructured":"Eibl RH, Schneemann M (2022) Cell-free DNA as a biomarker in cancer. Extracell Vesicles Circ Nucl Acids 3:195\u2013215","journal-title":"Extracell Vesicles Circ Nucl Acids"},{"issue":"9","key":"11628_CR4","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park W, Chawla A, O\u2019Reilly EM (2021) Pancreatic cancer: a review. JAMA 326(9):851\u2013862","journal-title":"JAMA"},{"issue":"4","key":"11628_CR5","first-page":"82","volume":"36","author":"K Huang","year":"2023","unstructured":"Huang K, Ma JJ (2023) Design, synthesis, PD-1\/PD-L1 inhibitory activity screening and molecular docking study of biphenyl compounds bearing triazine structure. J Liaocheng Univ 36(4):82\u201392","journal-title":"J Liaocheng Univ"},{"issue":"5","key":"11628_CR6","first-page":"71","volume":"32","author":"YY Zhu","year":"2019","unstructured":"Zhu YY, Huang K, Wang Y, Ma JJ (2019) Advance on HDAC multi-target inhibitors in the treatment of cancer. J Liaocheng Univ 32(5):71\u201379","journal-title":"J Liaocheng Univ"},{"key":"11628_CR7","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","volume":"8","author":"ZL Liu","year":"2023","unstructured":"Liu ZL, Chen HH, Zheng LL, Sun LP, Shi L (2023) Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther 8:198","journal-title":"Signal Transduct Target Ther"},{"key":"11628_CR8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12918-015-0201-z","volume":"9","author":"RJ Bender","year":"2015","unstructured":"Bender RJ, Mac Gabhann F (2015) Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis. BMC Syst Biol 9:55","journal-title":"BMC Syst Biol"},{"key":"11628_CR9","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nrm1911","volume":"7","author":"AK Olsson","year":"2006","unstructured":"Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L (2006) VEGF receptor signalling in control of vascular function. Nat Rev Mol Cell Biol 7:359\u2013371","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"12","key":"11628_CR10","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.3390\/biom10121673","volume":"10","author":"F Shaik","year":"2020","unstructured":"Shaik F, Cuthbert GA, Homer-Vanniasinkam S, Muench SP, Ponnambalam S, Harrison MA (2020) Structural basis for vascular endothelial growth factor receptor activation and implications for disease therapy. Biomolecules 10(12):1673","journal-title":"Biomolecules"},{"key":"11628_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.599281","volume":"8","author":"XR Wang","year":"2020","unstructured":"Wang XR, Bove AM, Simone G, Ma BY (2020) Molecular bases of VEGFR-2-mediated physiological function and pathological role. Front Cell Dev Biol 8:599281","journal-title":"Front Cell Dev Biol"},{"issue":"9","key":"11628_CR12","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1080\/13543776.2017.1344215","volume":"27","author":"FW Peng","year":"2017","unstructured":"Peng FW, Liu DK, Zhang QW, Xu YG, Shi L (2017) VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016). Expert Opin Ther Pat 27(9):987\u20131004","journal-title":"Expert Opin Ther Pat"},{"key":"11628_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115626","volume":"5","author":"M Moradi","year":"2023","unstructured":"Moradi M, Mousavi A, Emamgholipour Z, Giovannini J, Moghimi S, Peytam F, Honarmand A, Bach S, Foroumadi A (2023) Quinazoline-based VEGFR-2 inhibitors as potential anti-angiogenic agents: a contemporary perspective of SAR and molecular docking studies. Eur J Med Chem 5:115626","journal-title":"Eur J Med Chem"},{"issue":"45","key":"11628_CR14","doi-asserted-by":"publisher","first-page":"33384","DOI":"10.1039\/D4RA05244G","volume":"14","author":"PJ Chaudhari","year":"2024","unstructured":"Chaudhari PJ, Nemade AR, Shirkhedkar AA (2024) Recent updates on potential of VEGFR-2 small-molecule inhibitors as anticancer agents. RSC Adv 14(45):33384\u201333417","journal-title":"RSC Adv"},{"key":"11628_CR15","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nrc2442","volume":"8","author":"G Bergers","year":"2008","unstructured":"Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592\u2013603","journal-title":"Nat Rev Cancer"},{"key":"11628_CR16","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jprot.2017.08.015","volume":"170","author":"S Vyse","year":"2018","unstructured":"Vyse S, McCarthy F, Broncel M, Paul A, Wong JP, Bhamra A, Huang PH (2018) Quantitative phosphoproteomic analysis of acquired cancer drug resistance to pazopanib and dasatinib. J Proteomics 170:130\u2013140","journal-title":"J Proteomics"},{"key":"11628_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/978-3-319-91442-8_5","volume":"211","author":"C Gr\u00fcllich","year":"2018","unstructured":"Gr\u00fcllich C (2018) Cabozantinib: multi-kinase inhibitor of MET, AXL, RET, and VEGFR2. Recent Results Cancer Res 211:67\u201375","journal-title":"Recent Results Cancer Res"},{"issue":"11","key":"11628_CR18","doi-asserted-by":"publisher","first-page":"5420","DOI":"10.1016\/j.ejmech.2010.09.002","volume":"45","author":"K Lee","year":"2010","unstructured":"Lee K, Jeong KW, Lee YJ, Song JY, Kim MS, Lee GS, Kim YM (2010) Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors. Eur J Med Chem 45(11):5420\u20135427","journal-title":"Eur J Med Chem"},{"issue":"15","key":"11628_CR19","doi-asserted-by":"publisher","first-page":"5738","DOI":"10.1016\/j.bmc.2010.05.063","volume":"18","author":"J Dietrich","year":"2010","unstructured":"Dietrich J, Hulme C, Hurley LH (2010) The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec\u00ae, Nexavar\u00ae, and BIRB-796. Bioorg Med Chem 18(15):5738\u20135748","journal-title":"Bioorg Med Chem"},{"issue":"19","key":"11628_CR20","doi-asserted-by":"publisher","first-page":"8797","DOI":"10.1021\/acs.jmedchem.8b00938","volume":"61","author":"JG Kettle","year":"2018","unstructured":"Kettle JG, Anjum R, Barry E, Bhavsar D, Brown C, Boyd S, Campbell A, Goldberg K, Grondine M, Guichard S, Hardy CJ, Hunt T, Jones RDO, Li X, Moleva O, Ogg D, Overman RC, Packer MJ, Pearson S, Schimpl M, Shao W, Smith A, Smith JM, Stead D, Stokes S, Tucker M, Ye Y (2018) Discovery of N-(4-{[5-fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1H-1,2,3-triazol-1-yl]acetamide (AZD3229), a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors. J Med Chem 61(19):8797\u20138810","journal-title":"J Med Chem"},{"issue":"1","key":"11628_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1021\/ml500394m","volume":"6","author":"K Okamoto","year":"2014","unstructured":"Okamoto K, Ikemori-Kawada M, Jestel A, von K\u00f6nig K, Funahashi Y, Matsushima T, Tsuruoka A, Inoue A, Matsui J (2014) Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization. ACS Med Chem Lett 6(1):89\u201394","journal-title":"ACS Med Chem Lett"},{"issue":"45","key":"11628_CR22","doi-asserted-by":"publisher","first-page":"18281","DOI":"10.1073\/pnas.1207759109","volume":"109","author":"M McTigue","year":"2012","unstructured":"McTigue M, Murray BW, Chen JH, Deng YL, Solowiej J, Kania RS (2012) Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors. Proc Natl Acad Sci USA 109(45):18281\u201318289","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"11628_CR23","doi-asserted-by":"publisher","first-page":"5712","DOI":"10.1080\/07391102.2021.1872417","volume":"40","author":"SJ Modi","year":"2022","unstructured":"Modi SJ, Kulkarni VM (2022) Exploration of structural requirements for the inhibition of VEGFR-2 tyrosine kinase: binding site analysis of type II, \u201cDFG-out\u201d inhibitors. J Biomol Struct Dyn 40(12):5712\u20135727","journal-title":"J Biomol Struct Dyn"},{"issue":"41","key":"11628_CR24","doi-asserted-by":"publisher","first-page":"28462","DOI":"10.1039\/D3RA05542F","volume":"13","author":"YL Gao","year":"2023","unstructured":"Gao YL, Li F, Ni X, Yang SW, Liu H, Wu XY, Liu JQ, Ma JJ (2023) Design, synthesis and biological evaluation of VEGFR-2\/HDAC dual inhibitors as multitargeted antitumor agents based on fruquintinib and vorinostat. RSC Adv 13(41):28462\u201328480","journal-title":"RSC Adv"},{"issue":"12","key":"11628_CR25","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","volume":"10","author":"FM Yakes","year":"2011","unstructured":"Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, Orf J, You A, Laird AD, Engst S, Lee L, Lesch J, Chou YC, Joly AH (2011) Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 10(12):2298\u20132308","journal-title":"Mol Cancer Ther"},{"issue":"22","key":"11628_CR26","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.4155\/fmc-2022-0188","volume":"14","author":"H Li","year":"2022","unstructured":"Li H, Gao Y, Ma JJ (2022) Advances in nonclassical phenyl bioisosteres for drug structural optimization. Future Med Chem 14(22):1681\u20131692","journal-title":"Future Med Chem"},{"issue":"19","key":"11628_CR27","doi-asserted-by":"publisher","first-page":"14046","DOI":"10.1021\/acs.jmedchem.1c01215","volume":"64","author":"MAM Subbaiah","year":"2021","unstructured":"Subbaiah MAM, Meanwell NA (2021) Bioisosteres of the phenyl ring: recent strategic applications in lead optimization and drug design. J Med Chem 64(19):14046\u201314128","journal-title":"J Med Chem"},{"issue":"7","key":"11628_CR28","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.1021\/jm300094u","volume":"55","author":"AF Stepan","year":"2012","unstructured":"Stepan AF, Subramanyam C, Efremov IV, Dutra JK, O\u2019Sullivan TJ, DiRico KJ, McDonald WS, Won A, Dorff PH, Nolan CE, Becker SL, Pustilnik LR, Riddell DR, Kauffman GW, Kormos BL, Zhang L, Lu Y, Capetta SH, Green ME, Karki K, Sibley E, Atchison KP, Hallgren AJ, Oborski CE, Robshaw AE, Sneed B, O\u2019Donnell CJ (2012) Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active \u03b3-secretase inhibitor. J Med Chem 55(7):3414\u20133424","journal-title":"J Med Chem"},{"issue":"12","key":"11628_CR29","doi-asserted-by":"publisher","first-page":"3976","DOI":"10.1016\/j.ica.2006.04.006","volume":"359","author":"BS Creaven","year":"2006","unstructured":"Creaven BS, Egan DA, Kavanagh K, McCann M, Noble A, Thati B, Walsh M (2006) Synthesis, characterization and antimicrobial activity of a series of substituted coumarin-3-carboxylatosilver(I) complexes. Inorg Chim Acta 359(12):3976\u20133984","journal-title":"Inorg Chim Acta"},{"key":"11628_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cdc.2020.100341","volume":"25","author":"N Khaldi-Khellafi","year":"2020","unstructured":"Khaldi-Khellafi N, Oukacha-Hikem D, Terrachet-Bouaziz S, Abdoun A, Makhloufi-Chebli M, Dumas F, Silva AMS, Hamdi M (2020) Green synthesis, characterization, structure, biological activity, theoretical calculations and drug-likeness analysis of coumarins. Chem Data Collect 25:100341","journal-title":"Chem Data Collect"},{"issue":"39","key":"11628_CR31","doi-asserted-by":"publisher","first-page":"7016","DOI":"10.1016\/j.tet.2014.07.032","volume":"70","author":"U Kayal","year":"2014","unstructured":"Kayal U, Karmakar R, Banerjee D, Maiti G (2014) Copper oxide catalyzed domino process for the synthesis of substituted 2H-pyran-2-ones and polyhydroxy coumarin derivatives. Tetrahedron 70(39):7016\u20137021","journal-title":"Tetrahedron"},{"issue":"14","key":"11628_CR32","doi-asserted-by":"publisher","first-page":"6277","DOI":"10.1021\/acs.jmedchem.8b00672","volume":"61","author":"I Szabadkai","year":"2018","unstructured":"Szabadkai I, Torka R, Garamv\u00f6lgyi R, Baska F, Gyulav\u00e1ri P, Boros S, Illy\u00e9s E, Choidas A, Ullrich A, \u0150rfi L (2018) Discovery of N-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as novel AXL kinase inhibitors. J Med Chem 61(14):6277\u20136292","journal-title":"J Med Chem"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-026-11628-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-026-11628-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-026-11628-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:55:49Z","timestamp":1793814949000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-026-11628-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":32,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["11628"],"URL":"https:\/\/doi.org\/10.1007\/s11030-026-11628-w","relation":{},"ISSN":["1573-501X"],"issn-type":[{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"16 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}